Commercialization Review Committee

Printer-friendly versionSend by email

The CCRM team continues to actively search for high potential Regenerative Medicine (RM) assets, primarily within its member institutions, as well as globally.

 

The function of the Commercialization Review Committee (CRC) is to review and recommend technologies and projects for investment by CCRM, the business cases for the RM assets and recommend in-licensing and a commercialization strategy for focused commercial development of technology. The CRC is composed of industry experts, members of the Board of Directors, representatives from the Industry Consortium and staff of Member Technology Transfer Offices. CCRM is pleased to have Devyn Smith, PhD as Chair of the CRC.